| Biotechnology Industry | Healthcare Sector | Mr. Peter Buhl Jensen Adj Professor, M.D., Ph.D. CEO | XSTO Exchange | - ISIN |
| DE Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Chosa Oncology AB, previously known as Chosa ApS, is a pioneering company in the field of oncology drug development, focusing on creating innovative treatments for cancer. Founded and incorporated in 2022, the company is strategically located in Lund, Sweden, leveraging the region's strong life sciences ecosystem. Chosa Oncology AB is dedicated to advancing cancer therapy by developing drugs that can significantly improve patient outcomes. As a relatively new entrant in the oncology sector, the company aims to bring groundbreaking solutions to the forefront of cancer treatment, addressing the urgent need for more effective and targeted therapies.
Chosa Oncology AB is in the early stages of its journey to become a leader in the oncology field. The company's product pipeline and services are focused on developing and offering novel oncology drugs designed to treat a wide range of cancers. While specific drug candidates or therapies being developed are not detailed, the company's research and development efforts are centered around: